Navigation Links
Clostridium difficile Infection: Strategic Approaches for Better Outcomes
Date:6/15/2009

Complimentary Continuing Education Live Lectures for Healthcare Professionals

VOORHEES, N.J., June 15 /PRNewswire/ -- In recent years, the epidemiology of Clostridium difficile infection (CDI) has been changing. This trend may be the result of antimicrobial use, infection control practices, or other factors. It is critical for healthcare professionals to be aware of the epidemiology of this virulent pathogen and apply evidence-based principles for diagnosis, treatment, and prevention.

To address the need for current education on CDI, Robert Michael Educational Institute LLC (RMEI) and Postgraduate Institute for Medicine (PIM) are jointly sponsoring complimentary continuing education lectures conveniently located at medical institutions across the United States. This activity is supported by an educational grant from ViroPharma Incorporated and is accredited for physicians, pharmacists, and registered nurses.

Faculty for these lectures are leading experts in infectious diseases, gastroenterology, microbiology, epidemiology, and infection control.

Healthcare professionals can visit www.RMEI.com/CDILectures, e-mail CDILectures@RMEI.com, or call toll-free to 1-866-992-9940 to schedule a lecture.

"Robert Michael Educational Institute LLC is committed to providing healthcare professionals with opportunities for quality, innovative, and convenient continuing medical education," says President and CEO, Robert M. Colleluori.

RMEI is a medical education company that specializes in independent, certified, and non-certified education. The goal of all certified RMEI educational offerings is to promote a spirit of lifelong learning and continuous professional development. RMEI works closely with medical experts to design activities that improve diagnosis and treatment leading to better outcomes for patients. These activities include national and international symposia, teleconferences, live meetings, enduring print materials, and interactive Internet programs.

For other educational opportunities, please visit www.RMEI.com.


'/>"/>
SOURCE Robert Michael Educational Institute LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
2. Clostridium difficile Infection: Current Challenges and Controversies
3. Germgards Ultra-Fast Hand Hygiene Solution Protects Against Deadly MRSA, C difficile, and Influenza Virus
4. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
5. Strategic Diagnostics Updates Roth Conference Presentation Time
6. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
7. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
8. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
9. Genstar Names Michael Hurt to Its Strategic Advisory Board
10. Pharsight Expands Strategic Consulting Services Team
11. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Mar 23, 2017 Research and Markets ... Markets" report to their offering. ... The Global Market for ... in 2016 at a CAGR of 8.9%, ... non-energetic bioproducts into seven major product segments: bio-derived chemicals, biofuels, ...
(Date:3/23/2017)... , March 23, 2017  SeraCare Life ... global in vitro diagnostics manufacturers and clinical ... industry,s first multiplexed Inherited Cancer reference ... by next-generation sequencing (NGS). The Seraseqâ„¢ Inherited ... with input from industry experts to validate ...
(Date:3/23/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX), a ... market, today reported financial results for the quarter ... provide an update on the company,s clinical development ... "We are pleased to report that last year ... President Anja Krammer. "We achieved key clinical milestones ...
(Date:3/23/2017)... SEATTLE , March 23, 2017 ... translational development of novel therapies in immuno-oncology, today ... to lead" small molecule compounds that activate interferon ... (RLR) pathways and demonstrate immune-mediated tumor regression in ... in the study who demonstrated complete tumor regression ...
Breaking Biology Technology:
(Date:3/22/2017)... March 21, 2017 Optimove , ... by retailers such as 1-800-Flowers and AdoreMe, today ... Recommendations and Replenishment. Using Optimove,s machine learning algorithms, ... product and replenishment recommendations to their customers based ... predictions of customer intent drawn from a complex ...
(Date:3/20/2017)... PMD Healthcare announces the release of its ... System (WMS), a remote, real-time lung health monitoring and ... is a Medical Device, Digital Health, and Chronic Care ... innovative solutions that empower people to improve their healthcare ... developed the first ever personal spirometer, Spiro PD, which ...
(Date:3/9/2017)... , Australia , March 9, 2017 ... data at the prestigious World Lung Imaging Workshop at ... Andreas Fouras , was invited to deliver the latest ... medicine. This globally recognised event brings together leaders at ... the latest developments in lung imaging. ...
Breaking Biology News(10 mins):